Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice

Study acronym: RELI
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Mar 15, 2027 → Aug 15, 2027
See other at-risk trials from Maastricht University Medical Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Start date changed from estimate of Mar 15, 2026 to Jun 15, 2026
    • Primary completion pushed from Mar 15, 2027 to Aug 15, 2027
    • Site details revised
    • Eligibility criteria expanded, about 5 words
  2. Minor Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Basal cell carcinoma (BCC) is the most common skin cancer in the Netherlands, with incidence rates continuing to rise. The current diagnostic standard combines clinical evaluation and dermoscopy, while biopsy followed by histopathological examination remains the gold standard when uncertainty about the diagnosis persists. However, biopsy is invasive, time-consuming, and costly. Line-field confocal optical coherence tomography (LC-OCT) is a non-invasive imaging technique that has emerged as a promising alternative to biopsy for BCC suspected lesions. This retrospective study aims to evaluate the real-world clinical performance of LC-OCT in routine dermatological practice, where it has been integrated into the diagnostic work-up for BCC-suspect lesions.
Trial Details
NCT Number NCT07501780
Lead Sponsor Maastricht University Medical Center
Collaborators: Mohs Klinieken
Conditions
(from sponsor)
Basal Cell Carcinoma of Skin, Optical Coherence Tomography (OCT), Neoplasms, Neoplasms, Basal Cell, Carcinoma, Basal Cell (BCC), Real-world Study, Implementation
Related terms Basal Cell Carcinoma, Carcinoma, Neoplasms, Neoplasms, Basal Cell
Enrollment 297 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov